A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Trial details
- Registry ID
- NCT07188558
- Drugs studied
- axicabtagene ciloleucel, lisocabtagene maraleucel, rondecabtagene autoleucel
TrialRedline tracks 2 clinical trials sponsored by Lyell Immunopharma, Inc.: 1 Phase 3, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyNCT07188558 | axicabtagene ciloleucel, lisocabtagene maraleucel, rondecabtagene autoleucel | Recruiting | 2029-12Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| LYL273 for Patients With Relapsed or Refractory mCRCNCT05319314 | LYL273 | Recruiting | 2028-06Estimated |
Names as written in the registry records.
NCT07188558 · Lyell Immunopharma, Inc.
Before: Not yet recruiting. After: Recruiting.